Siegfried Priglinger

Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials

Jeffrey S. Heier, Eleonora M. Lad, Frank G. Holz et al. · The Lancet · 2023 · 372 citations

Ocular Disease, Ophthalmology, Age-related Diseases +4

Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

Arshad M. Khanani, Sunil Patel, Giovanni Staurenghi et al. · The Lancet · 2023 · 263 citations · Full text

Clinical Epidemiology, Clinical Trials, Geographic Atrophy +5

The Protective Effect of Quercetin against Oxidative Stress in the Human RPE In Vitro

Daniel Kook, Armin Wolf, Alice L. Yu et al. · Investigative Ophthalmology & Visual Science · 2008 · 157 citations

An in vivo evaluation of Brilliant Blue G in animals and humans

Matthias Remy, Sebastian Thaler, Ricarda G. Schumann et al. · British Journal of Ophthalmology · 2008 · 148 citations

COMPLIANCE AND ADHERENCE OF PATIENTS WITH DIABETIC MACULAR EDEMA TO INTRAVITREAL ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN DAILY PRACTICE

Dawn A. Sim, Tina Herold, Ricarda G. Schumann et al. · Retina · 2017 · 146 citations · Full text